Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from plasma-derived to recombinant factor VIII after 50 exposure days in previously untreated severe hemophilia A
2017-005197-19Phase 4Terminated
- Sponsor
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of plasma-derived factor VIII, recombinant human coagulation factor VIII in hemophilia A, sponsored by IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico. Started Mar 2019; status: terminated.
02
Drugs
plasma-derived factor VIIIrecombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2017-005197-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005197-19.